amikacin + ceftazidime

Amikacin + ceftazidime is a combination of two antibiotics used primarily for the empirical treatment of serious bacterial infections, especially in immunocompromised patients such as those with febrile neutropenia. Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of bacteria, inhibiting protein synthesis and leading to cell death. Ceftazidime is a third-generation cephalosporin (a beta-lactam antibiotic) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis and death. The combination provides broad-spectrum coverage against Gram-negative bacteria, including Pseudomonas aeruginosa, and some Gram-positive organisms. This regimen has been widely used as initial therapy for febrile neutropenia in cancer patients[1][5].

Other names

amikacin plus ceftazidimeamikacin and ceftazidimeCA regimen